Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 98 clinical trials
Featured trial
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined

combination chemotherapy
cyclophosphamide
methotrexate
thioguanine
asparaginase
  • 5 views
  • 28 Oct, 2022
  • 94 locations
Featured trial
AHEP0731: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed Liver Cancer

AHEP0731: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed Liver Cancer

  • 440 views
  • 07 Nov, 2020
  • 1 location
Featured trial
AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

  • 171 views
  • 08 Nov, 2020
  • 1 location
Combination Chemotherapy in Patients With Newly Diagnosed BPDCN (LpDessai)

Patients with suspected BPDCN and meeting eligibility criteria will be enrolled in the study. First, BPDCN diagnosis will be confirmed by anatomic pathology (Dr Petrella T, Montreal) and cytologic plus immunophenotyping analysis (Pr Garnache Ottou F, UMR1098 BESANCON). Patients will then receive three 21 days cycles of a combination of …

  • 0 views
  • 16 Jun, 2022
  • 2 locations
Pancreatic Adenocarcinoma Neoadjuvant Combination Chemotherapy and Stereotactic Body Radiation Therapy Before Surgery

This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving radiation therapy with Stereotactic body radiation therapy (SBRT) and chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by pancreatectomy.

  • 0 views
  • 04 Oct, 2022
  • 1 location
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer

Pancreatic cancer represents the most lethal of the common malignancies with a 5-year survival rate of less than 5%. For patients who are eligible for potentially curative resection, despite mortality and morbidity rates after surgery have improved, the recurrence rate is up to 85% within 2 years. FOLFIRINOX (fluoropyrimidine/leucovorin plus …

  • 16 views
  • 26 Feb, 2022
  • 2 locations
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (ESPERO)

Optimal salvage treatment for HER2-positive breast cancer after trastuzumab and T-DM1 failure still remains to be established. We would like to investigate the efficacy and safety of combination

  • 0 views
  • 07 Oct, 2022
  • 1 location
Etoposide and Cisplatin in Treating Young Patients With Previously Untreated High-Risk Neuroblastoma Undergoing High-Dose Chemotherapy Stem Cell Transplant and Isotretinoin

(combination chemotherapy) and giving them in different doses may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Peripheral blood stem cell transplant using

conventional surgery
combination chemotherapy
tumor cells
etoposide
carboplatin
  • 24 views
  • 07 Nov, 2020
  • 1 location
Neoadjuvant Therapy Followed by Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer

The purpose of this study is to evaluate a new treatment routine for patients with borderline resectable and unresectable pancreas cancers.

gemcitabine
neutrophil count
karnofsky performance status
adenocarcinoma
measurable disease
  • 9 views
  • 08 Nov, 2020
  • 1 location
PAXG Out in the Country

The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.

gemcitabine
metastasis
paclitaxel
neutrophil count
pdac
  • 0 views
  • 19 Feb, 2021
  • 30 locations